ClinicalTrials.gg
CompletedNCT05265325Updated Jun 28, 2024

A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis

A Phase 2 interventional study of AND017 capsules TIW and AND017 capsules QW in Renal Anemia, sponsored by Kind Pharmaceuticals LLC. Completed at 25 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-28.

Sponsored by Kind Pharmaceuticals LLC · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2024, 2 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 115 studies in Anemia with a site in China — 33 open to participants now, 42 under way, 8 of them phase 3. Anemia · China.

Enrollment
34th of 97
175 · median 120
Started
2023
with 14 others
Phase 2
22 of 115
6 open now
Registered
61st of 115
by date
Lead sponsor
4 of 115
Kind Pharmaceuticals LLC

Among the 115 studies in Anemia with a site in China, this one is the 34th largest by enrollment of the 97 interventional ones that give a count, is one of 15 that started in 2023, is one of 22 in phase 2, and was the 61st registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

33 of the 115 studies in Anemia with a site in China are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Anemia with a site in China, or all of them as a file.
02

Study summary

This is a phase II study to evaluate the safety and efficacy of AND017 in renal anemia patients on dialysis

Read the detailed description

This is a Phase II study to assess the safety and efficacy of AND017 in patients with CKD who are anemic and on dialysis.

03

Conditions studied

  • Renal Anemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Body weight from 45 to 140 kg inclusive
  2. Receiving stable HD (including combination methods such as hemodiafiltration or hemofiltration), HHD, or PD for ESKD for a minimum of 16 weeks prior to randomization and determined by the Investigator to be compliant with dialysis treatment prescription.
  3. Patient must have been on IV or SC of an approved ESA under the prescription for at least 6 weeks, and ≤25% change in dose between the two most recent doses, prior to randomization.
  4. The mean of two values during screening (at least 7 days apart) must be 9.0-11.0 g/dL with a difference of ≤1.3 g/dL between the two values
  5. TSAT ≥ 20% or ferritin ≥ 100 ng/mL at screening
  6. Folate ≥ 3.0 ng/mL and vitamin B12 ≥ lower limit of normal (LLN) at screening
  7. and ALT \< 3× at screening.
  8. No evidence of other causes of anemia caused by a pathologic process in the hematopoietic system, including intra- or extravascular hemolysis, or myelodysplasia.

Key Exclusion Criteria:

  1. Concurrent retinal neovascular lesions requiring treatment including proliferative diabetic retinopathy, exudative age-related macular degeneration, retinal vein occlusion, macular edema, etc.
  2. Anemia determined by the Investigator to be caused by concurrent disease with inflammatory symptoms (such as systemic erythematosus, ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis, Sjögren's syndrome, celiac disease, etc.).
  3. History of gastric/intestinal resection considered influential on the absorption of drugs in the gastrointestinal tract (excluding resection of gastric or colon polyps) or concurrent symptomatic gastroparesis despite on treatment.
  4. bleeding (eg, requiring transfusion or drop in Hb of ≥ 2 g/dL) within 4 weeks of first dose; bleeding diathesis or risk of bleeding that has not been medically or surgically corrected at least 4 weeks prior to first dose of study drug.
  5. Uncontrolled hypertension defined as patients with hypertension having more than one of three diastolic blood pressure values >95 mmHg and each test at least 5 min apart during the screening assessment.
  6. Concurrent congestive heart failure ( [NYHA] Class III or higher).
  7. History of stroke, (TIA), myocardial infarction, thromboembolic event (deep vein thrombosis, DVT), pulmonary embolism, or lung infarction within 24 weeks before the screening assessment.
  8. Positive for surface antigen or anti- virus antibody at the screening assessment, or positive for in a past test.
  9. Not complying with COVID-19 prevention and control requirements per local policy.
  10. Concurrent primary form of anemia other than renal anemia (hemolytic anemia, thalassemia, sickle cell anemia, history of pure red cell aplasia, history of myelodysplastic syndrome or multiple myeloma, iron deficiency, etc.). Any question of the primary cause of anemia should be discussed with the Medical Monitor before the patient signs .
  11. Known hemosiderosis, hemochromatosis or hyper-coagulable condition
  12. Known to be hypersensitive or intolerant to ESA.
  13. Having received treatment with androgenic anabolic steroids, testosterone enanthate, or mepitiostane within 5 weeks prior to the first dose.
  14. Any treatment with a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) within 5 weeks prior to the first dose.
  15. >1.5 ULN, or AST>3 ULN, or ALT>3 ULN, or ALP>3 ULN, or previous or concurrent serious liver disease (acute or active chronic hepatitis, cirrhosis, etc.) thought to be caused by any other HIF-PHI.
  16. Previous or current malignant tumor (patients with no recurrence for at least 5 years are eligible. Exemption: basal cell and squamous cell carcinoma not under active stage).
  17. Patients with a history of significant liver disease or active liver disease.
  18. Patients that have major surgery planned during the study period.
  19. Patients that have undergone blood transfusion or with evidence of major blood loss within 8 weeks before the screening assessment. Investigators should discuss this with the Medical Monitor for cases where there is doubt about whether to exclude or not.
  20. Patients unable to discontinue IV iron during the screening period.
  21. Patients with an organ transplant on , or with a scheduled kidney or any other organ transplant within the duration of the study, or without kidney.
  22. Serum albumin \< 2.5 g/dL at screening.
  23. Patients with other chronic medical condition that may limit in the opinion of the Investigator.
  24. History of a seizure disorder or any occurrence of seizures in the past.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    AND017 Dose Regimen A

    AND017 will be administrated orally at dose A three times a week

    Drug: AND017 capsules TIW

  • Experimental
    AND017 Dose Regimen B

    AND017 will be administrated orally at dose B once a week

    Drug: AND017 capsules QW

  • Active comparator
    Erythropoietin stimulating agent

    Investigator will select an erythropoietin stimulating agent, such as epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars, for the patient under this arm with starting doses and dose adjustment rules according to the epoetin alfa USPI or SmPC.

    Drug: epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars

Interventions

  • Orally, 3 times per week in Period 1 and dose adjustment in Period 2 at 2 mg/4 mg and 2-weeks interval according to Hb levels

  • Orally, once per week in Period 1 and dose adjustment in Period 2 at 4 mg/8 mg and 2-weeks interval according to Hb levels

  • Drugepoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars

    Dose regimen and adjustment rules according to the USPI or SmPC or local practice

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Incidence of adverse events

    Time frame: Up to 20 weeks

  2. Mean change from baseline in Hb at Week 6

    Mean change from baseline in Hb at Week 6

    Time frame: Up to 5 weeks after dosing

Secondary outcomes

  1. Proportion of responders, during the entire study period.

    Responders are defined as patients whose Hb achieved ≥ 10.0 g/dL and an increase ≥ 1.0 g/dL from baseline

    Time frame: up to Week 20

  2. Mean proportion of visits at which patients maintain Hb within the target range from baseline during the fixed-dose period and titration period

    Target range is defined as 10.0-11.0 g/dL inclusive and an increase ≥ 1.0 g/dL.

    Time frame: up to Week 20

  3. Proportion of patients with a mean Hb between 10.0-11.0 g/dL inclusive during Week 14-20

    Proportion of patients with a mean Hb between 10.0-11.0 g/dL inclusive during Week 14-20

    Time frame: at Week 14, 15, 16, 17, 18, 19, and 20

  4. Change in Hb from baseline to the mean Hb levels over Week 14-20

    Change in Hb from baseline to the mean Hb levels over Week 14-20

    Time frame: Baseline and at Week 14, 15, 16, 17, 18, 19, and 20

  5. Mean Hb levels and mean change from baseline in Hb level at each visit

    Mean Hb levels and mean change from baseline in Hb level at each visit

    Time frame: up to Week 20

  6. Cumulative response rate over the entire study period

    Response is defined as Hb \< 10.0 g/dL or an increase in hemoglobin of \<1 g/dL from baseline

    Time frame: up to Week 20

Other outcomes

  1. EPO levels and change from baseline at each visit

    EPO levels and change from baseline at each visit

    Time frame: up to Week 20

  2. Hepcidin levels and change from baseline at each visit

    Hepcidin levels and change from baseline at each visit

    Time frame: up to Week 20

  3. Iron study levels and change from baseline at each visit

    Iron study levels and change from baseline at each visit

    Time frame: up to Week 20

07

Study locations

25 sites
  • US Renal Care - Pine Bluff
    Pine Bluff, Arkansas 71603, United States
  • North America Research Institute
    Riverside, California 92503, United States
  • Rocky Mountain Kidney Care
    Lone Tree, Colorado 80124, United States
  • Nephrology and Hypertension Specialists
    Dalton, Georgia 30720, United States
  • High Desert Nephrology Associates
    Gallup, New Mexico 87301, United States
  • Nephrology Associates of Western New York
    Cheektowaga, New York 14225, United States
  • Nephrology Consultants of Northwest Ohio - Toledo
    Toledo, Ohio 43613, United States
  • South Texas Renal Care Group - San Saba
    San Antonio, Texas 78207, United States
  • Clinical Advancement Center PLLC
    San Antonio, Texas 78212, United States
  • South Texas Renal Care Group
    San Antonio, Texas 78251, United States
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing 400010, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361001, China
  • Xiamen Branch, Zhongshan hospital affilicated to Fudan University
    Xiamen, Fujian 361004, China
  • Xiamen Fifth Hospital
    Xiamen, Fujian 361115, China
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan 471039, China
  • Renmin Hospital of Wuhan University
    Wuhan, Hunan 430064, China
  • The First People's Hospital of Changzhou
    Changzhou, Jiangsu 213004, China
  • Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210011, China
  • Second Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215025, China
  • The Affiliated Zhongshan Hospital of Dalian University
    Dalian, Liaoning 116001, China
  • Zhongshan Hospital affiliated to Fudan University
    Shanghai, Shanghai 200031, China
  • Jinshan Hospital Affiliated to Fudan University
    Shanghai, Shanghai 201508, China
  • First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shanxi 710063, China
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan 610032, China
  • Zigong First People's Hospital
    Zigong, Sichuan 643000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Feb 2024, 9 months.

Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 9 months is below that.

Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2022
First posted
Mar 3, 2022
StartActual
May 3, 2023
Primary completionActual
Feb 29, 2024
CompletionActual
Apr 25, 2024
Last update
Jun 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05265325
Lead sponsor
Kind Pharmaceuticals LLC
Responsible party
Sponsor
First posted
Mar 3, 2022
Start date
May 3, 2023
Primary completion
Feb 29, 2024
Completion
Apr 25, 2024
Last update
Jun 28, 2024

Study contacts

Yusha Zhu, MD, PhD
study director · Kind Pharmaceuticals LLC

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AND017

Start the discussion